|
It was reported that the patient with an implanted neurostimulator and leads experienced new sacroiliac-area pain unrelated to baseline pain, pain at the neurostimulator/battery site, and an abrasive sensation around the battery site.During reprogramming on (b)(6)2026, the patient reported leg heaviness, suspected high stimulation, and requested stimulation adjustment.The abrasive sensation had been present immediately before reprogramming.Device impedance testing was optimal, no signs of overstimulation were observed, and programming adjustments were made.The patient later reported that the leg heaviness was part of the pre-implant pain.The patient attempted to lower the device settings and subsequently turned the device off; normal baseline pain returned with the device off, while the new sacroiliac-area pain and abrasive battery-site sensation persisted.The patient contacted the healthcare provider on (b)(6)2026 regarding recurrent pain and abrasive sensation.On (b)(6)2026, the physician advised the patient to return for sacroiliac- area epidural injections and further evaluation of the operative/implant site, planned for (b)(6)2026.No rash, redness, oozing, or other issues were reported.The pain and abrasive sensation were ongoing. the manufacturer representative (rep) indicated they would send any further information as they become aware.
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|